Conclusions: This initial data demonstrates that the shunt device can be safely implanted and early clinical improvement can be obtained in patients with heart failure and preserved or mildly reduced ejection fraction. Longer term follow-up is warranted.
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Background: Although Clopidogrel pretreatment is recommended (class I-C) for stable CAD patients scheduled for elective PCI, the benefit of this strategy compared to an administration at the time of PCI has not been shown on hard clinical outcome. We performed a systematic review and meta-analysis of all RCTs to evaluate the impact of clopidogrel pretreatment on mortality and major bleeding after elective PCI for stable CAD, as compared with no pretreatment. An additional metaanalysis was done on registries. Methods: We included studies on elective PCI from MEDLINE, EMBASE, CCTR databases that reported clinical data on mortality and major bleeding. A random-effect model was applied. Pretreatment was defined as the administration of clopidogrel before PCI. The primary efficacy and safety endpoints were all-cause mortality and major bleeding, respectively. Secondary endpoints included MACE, MI, Stroke, UVR, Stent Thrombosis (ST), minor and any bleeding. Results: Of the 392 titles identified, 6 (3 RCTs and 3 observational) met the inclusion criteria, published between Aug-2004 and Dec-2012. Of 13628 patients, 1636 were from RCTs. 55% underwent PCI. Results from the analysis of RCTs are shown in Figure I . ST, stroke and UVR were not different between groups. In the analysis of observational data, there was no difference between groups for all cause death, MI and ST, nor in bleeding. Only MACE and UVR were decreased.
Conclusions: Clopidogrel pretreatment is not associated with a reduction of mortality, MACE or ischemic endpoints in stable CAD scheduled for elective PCI, but with an excess of minor and any bleeding.
TCT-138
Clopidogrel Pretreatment in Non ST Elevation Acute Coronary Syndroms: no effect on mortality, decrease in ischemic endpoints at a price of more major bleeding. Background: Clopidogrel pretreatment is recommended for the treatment of NSTEACS patients (class I-B), at a time when the final revascularization strategy is not known. A previous meta-analysis focused on randomized trials suggested a tiny benefit in patients undergoing PCI. We performed a new meta-analysis of not only RCTs but also registries to assess the impact of clopidogrel pretreatment in NSTEACS patients. We evaluated the global effect independently of revascularization ("All" analysis) and in patients undergoing PCI ("PCI" analysis). Methods: We included studies on NSTEACS from MEDLINE, EMBASE, CCT and Biomedcentral. A random-effect model was applied. Pretreatment was defined as the administration of clopidogrel before PCI or catheterization. Primary efficacy and safety endpoints were all-cause mortality and major bleeding respectively, at longest follow up available. Secondary endpoints included Major Adverse Cardiac Events (MACE), Stroke, Stent Thrombosis, UVR. Results: Of the 393 titles identified, 6 articles (3 RCTs and 3 observational studies) met the inclusion criteria, published between August 2004 and January 2013, including 28 350 patients, in those 14 678 from RCTs. 52% underwent PCI. Among NSTEACS patients, clopidogrel pretreatment was not associated with a lower risk of mortality ("all": OR¼0,85, 95%CI(0,66-1,08), p¼0,18 or "PCI": OR¼0,81, 95% CI(0,58-1,13), p¼0,22). When considering all of studies (RCTs and registries) together, the reduction in Ischemic endpoints (OR¼0,81, 95%CI(0,7-0,94), p¼0,006) is counterbalanced by an increase in major bleeding (OR¼1,28, 95%CI(1,12-1,46), p¼0,0002). The reduction in ischemic endpoints is no more significant in the "PCI" analysis (OR¼0,82, 95%CI(0,65-1,03), p¼0,10) while there is still an excess of major bleeding in these patients (OR¼1,2, 95%CI(1-1,44), p¼0,048). ST, stroke and UVR were not different between groups (pretreatment vs. no) in both analyses. Conclusions: Clopidogrel pretreatment is not associated with a reduction of mortality in NSTEACS patients; the reduction of MACE is counterbalanced by major bleeding for "all" and "PCI" patients. The concept of systematic pretreatment in NSTE-ACS patients needs reappraisal in the contemporary era.
TCT-139
The effect of glycoprotein IIb/IIIa inhibitors on mortality and MACE following PCI for NSTEMI/UA James P. Howard Background: Meta-analyses of PCI in NSTEMI/UA have shown GPIIbIIIa inhibitors to be associated with a reduction in major adverse cardiac events at 30 days. However, many of the trials were carried out before the routine use P2Y12 inhibitors which act up-stream of GPIIbIIIa mediated platelet aggregation. Studies performed in the clopidogrel yield conflicting results and registry data indicates that these agents are less safe than trials would indicate. Methods: We undertook an observational study at an interventional cardiology center involving 5,227 patients undergoing PCI for NSTEMI/UA and receiving clopidogrel and aspirin. GPIIbIIIa use was at the discretion of the operator. Primary outcome was all cause mortality assessed at a median follow up of 4.6 years (IQR 3.0 -6.2 years). Results: 43.6% of patients were treated with GP IIb/IIIa inhibitors. The patients were younger, more likely to be male, and have fewer comorbidities including previous MI, CKD and PVD. They were less likely to suffer multivessel disease and more likely to have a successful angiographic result. Kaplan-Meier analysis showed GP IIbIIIa inhibitor use was associated with improved survival (p<0.001) and reduced MACE (p¼0.011), but increased bleeding (p¼0.001). On multivariate analysis the benefits were lost for both survival (HR 0.876; 95% CI 0.693 -1.108; p¼0.501) and MACE (HR 1.036; 95% CI 0.883 -1.216). OCTOBER 29, 2013, 3:30 PM-5:30 PM www.jacctctabstracts2013.com
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